Welcome to our dedicated page for Staar Surg news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surg stock.
Staar Surgical Co (STAA) delivers innovative vision correction solutions through advanced implantable lenses for refractive and cataract surgery. This news hub provides investors and medical professionals with essential updates on the company's technological advancements and market position.
Access consolidated coverage of earnings reports, product approvals, and strategic partnerships impacting the ophthalmic devices sector. Our repository includes official press releases about ICL technology developments, international regulatory milestones, and clinical study outcomes.
Stay informed about STAA's progress in minimally invasive surgical solutions through verified updates on manufacturing expansions, R&D investments, and surgeon training initiatives. Bookmark this page for real-time tracking of developments affecting the company's role in improving global vision care standards.
STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses (EVO ICL™), has announced its plans to release second quarter 2024 financial results on August 7, 2024, after market close. The company will host an earnings webcast at 4:15 p.m. ET / 1:15 p.m. PT on the same day to discuss financial results and operational progress. Investors can access the webcast through the company's website or a dedicated link. STAAR Surgical has been focused on ophthalmic surgery for over 40 years and has sold more than 3,000,000 ICLs in over 75 countries. The company operates manufacturing facilities in California and Switzerland.
STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses, announces its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. Patrick F. Williams, Chief Financial Officer, will engage in a fireside chat on August 13, 2024, at 8:30 a.m. Eastern Time. Investors and the public can access a live webcast of the event through STAAR's investor website.
STAAR Surgical, with over 40 years of focus on ophthalmic surgery, specializes in implantable lenses for visual freedom. Their EVO ICL™ product line has sold more than 3,000,000 ICLs globally, marketed in over 75 countries. The company operates facilities in California and Switzerland, continuing its commitment to innovative eye care solutions.
STAAR Surgical Company (NASDAQ: STAA), a leader in developing and marketing Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism, and presbyopia, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
Chief Financial Officer Patrick F. Williams will represent STAAR in a fireside chat on June 12, 2024, at 8:00 a.m. Eastern Time. The event will be webcast live, with a recording available on STAAR's investor website afterward.
STAAR has been dedicated to ophthalmic surgery for over 40 years, selling over 3 million ICLs in more than 75 countries. Headquartered in Lake Forest, CA, the company operates production facilities in the U.S. and Switzerland.
STAAR Surgical Company reported a 5% increase in net sales to $77.4 million for the first quarter of 2024. The company saw a 9% growth in ICL sales and a 2% increase in units. Gross margin was at 78.9%, and adjusted EBITDA was $5.3 million or $0.11 per share. However, there was a net loss of $3.3 million or $0.07 loss per share compared to net income of $2.7 million or $0.05 income per share in the previous year. STAAR Surgical reiterated its fiscal 2024 net sales outlook range of $335 million to $340 million and expects to be at the higher end of the range. Cash, cash equivalents, and investments available for sale were $252.1 million at the end of March 29, 2024.
STAAR Surgical Company (NASDAQ: STAA) has announced a strategic agreement with IQ Laser Vision, making EVO ICL lenses a primary option for patients seeking surgical vision correction in the U.S. This partnership aims to significantly increase the availability of EVO ICL lenses to qualified patients across IQ Laser Vision's practices.
STAAR Surgical Company (NASDAQ: STAA) announced the appointment of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel to drive innovation and growth. Nancy brings extensive experience from Johnson & Johnson, while Nate joins from NuVasive. This move reflects the company's commitment to enhancing brand awareness and legal functions globally. The new executives will play a vital role in accelerating growth and expanding the market for the EVO family of Implantable Collamer Lenses.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
